Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Accretive Health, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Accretive Health, Inc. : Accretive Health Reports Inducement Grant under NYSE Rule 303A.08

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2013 | 01:05pm CEST

Accretive Health, Inc. (NYSE: AH) today announced that pursuant to the employment agreement entered into with Stephen Schuckenbrock on April 2, 2013, the company granted to Mr. Schuckenbrock on April 3, 2013 a non-qualified stock option under the New York Stock Exchange inducement grant exception. The inducement grant was approved by the company's Board of Directors on April 1, 2013 and is being made as an inducement material to Mr. Schuckenbrock's acceptance of employment with the company, in accordance with New York Stock Exchange Rule 303A.08. The company previously announced that Mr. Schuckenbrock has been appointed President and Chief Executive Officer and a member of the company's Board of Directors, effective April 3, 2013.

The stock option is for the purchase of 2,903,801 shares of the company's common stock, with an exercise price of $9.56, which was the closing price of the company's common stock reported on the New York Stock Exchange on April 3, 2013. The stock option will vest and become exercisable on a ratable monthly basis over 48 months based on continued service to the company, subject to acceleration in specified circumstances.

Accretive Health is providing the above information regarding Mr. Schuckenbrock's inducement grant in accordance with New York Stock Exchange Rule 303A.08.

About Accretive Health

At Accretive Health, our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve (increasing healthcare access to all). For more information, visit www.accretivehealth.com.

Accretive Health, Inc.
Investor Relations:
Atif Rahim
Telephone: 312.324.5476
email: investorrelations@accretivehealth.com
or
Media:
Puneet Singh
Telephone: 330.565.6802
email: mediarelations@accretivehealth.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACCRETIVE HEALTH, INC.
09/16 ACCRETIVE HEALTH, INC. : Other Events (form 8-K)
09/09 ACCRETIVE HEALTH, INC. : Entry into a Material Definitive Agreement, Financial S..
08/04 ACCRETIVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
08/04 ACCRETIVE HEALTH, INC. : Results of Operations and Financial Condition, Financia..
08/04 Accretive Health Reports Second Quarter 2016 Results
07/28 Accretive Health Appoints Doug Berkson as Senior Vice President, Strategy & N..
07/21 Accretive Health to Release Second Quarter 2016 Results on August 4
06/30 ACCRETIVE HEALTH : MotoSKILL Shop Tech Training Introduces New Tools and Persona..
06/30 ACCRETIVE HEALTH : Announces Restructuring Plan to Align to Customer Needs and S..
06/29 ACCRETIVE HEALTH, INC. : Costs Associated with Exit or Disposal Activities, Fina..
More news
Sector news : Ambulance & Emergency Services
09/16 FTSE falls as banking stocks lose ground
09/14DJBusiness Watch -- WSJ
09/13DJUNITEDHEALTH : Optum Unit to Oversee Quest Diagnostics' Billing Processes
09/13DJUNITEDHEALTH : Optum Unit to Oversee Quest Diagnostic's Billing Processes
09/05DJFRESENIUS : to Buy Spanish Hospital Group Quironsalud for 5.76 Billion Euros
More sector news : Ambulance & Emergency Services
Advertisement
Financials ($)
Sales 2016 206 M
EBIT 2016 -29,4 M
Net income 2016 77,3 M
Debt 2016 26,4 M
Yield 2016 -
P/E ratio 2016 5,81
P/E ratio 2017
EV / Sales 2016 1,43x
EV / Sales 2017 0,84x
Capitalization 268 M
More Financials
Chart ACCRETIVE HEALTH, INC.
Duration : Period :
Accretive Health, Inc. Technical Analysis Chart | US00438V1035 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 50%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Steve J. Shulman Chairman
Christopher Simon Ricaurte Chief Financial Officer & Treasurer
Patrick L. Funck Chief Information Officer & Senior Vice President
Alex J. Mandl Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACCRETIVE HEALTH, INC.-12.68%253
FRESENIUS SE & CO KGAA7.46%43 509
HCA HOLDINGS INC11.09%28 364
FRESENIUS MEDICAL CARE..0.64%27 416
LABORATORY CORP. OF AM..11.44%14 017
DAVITA INC-4.85%13 686
More Results